世界のポイントオブケア/迅速診断市場(~2025年):製品別(ブドウ糖、感染症(C型肝炎、インフルエンザ)、凝固)、プラットフォーム別(マイクロフルイディクス、イムノアッセイ)、購入方法別(処方箋、OTC)、エンドユーザー別(病院、Eコマース、在宅医療)

◆英語タイトル:Point of Care/Rapid Diagnostics Market by Product (Glucose, Infectious Disease (Hepatitis C, Influenza), Coagulation), Platform (Microfluidics, Immunoassay), Mode of Purchase (Prescription, OTC), Enduser (Hospital, e-comm, Home Care) - Global Forecast to 2025
◆商品コード:MD2702
◆発行会社(リサーチ会社):MarketsandMarkets
◆発行日:2021年2月19日
◆ページ数:232
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD4,950 ⇒換算¥564,300見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥758,100見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥929,100見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarkets社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
MarketsandMarkets社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

マーケッツアンドマーケッツ社は、世界のポイントオブケア/迅速診断市場規模が2020年295億ドルから2025年506億ドルまで、年平均11.4%成長すると予測しています。本調査レポートでは、ポイントオブケア/迅速診断の世界市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、製品別(血糖モニタリング、心臓代謝モニタリング、感染症検査、凝固モニタリング、妊娠・生殖能力検査)分析、プラットフォーム別(イムノクロマトグラフィー、イムノアッセイ、マイクロ流体、ディップスティック、分子診断)分析、購入方法別(OTC、処方箋)分析、エンドユーザー別(外来診療施設、病院・救命救急センター、在宅医療、その他)分析、地域別分析、競争状況、企業情報などを掲載しています。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・ポイントオブケア/迅速診断の世界市場規模:製品別(血糖モニタリング、心臓代謝モニタリング、感染症検査、凝固モニタリング、妊娠・生殖能力検査)
・ポイントオブケア/迅速診断の世界市場規模:プラットフォーム別(イムノクロマトグラフィー、イムノアッセイ、マイクロ流体、ディップスティック、分子診断)
・ポイントオブケア/迅速診断の世界市場規模:購入方法別(OTC、処方箋)
・ポイントオブケア/迅速診断の世界市場規模:エンドユーザー別(外来診療施設、病院・救命救急センター、在宅医療、その他)
・ポイントオブケア/迅速診断の世界市場規模:地域別
・競争状況
・企業情報
【レポートの概要】

“The global point of care diagnostrics market size is projected to reach USD 50.6 billion by 2025 from USD 29.5 billion in 2020, at a CAGR of 11.4%.”
Factors such as the technological advancements in point of care devices in the market are propelling the growth of the market. Additionally, rising cases of investments from both private and public sectors boosting the research activities are likely to have affect in the growth of point of care diagnostics market. However, lack of prpper alignment of POCs with central lab methods, and lower adoption, due to lack of knowledge reagading the use of PoC products for indicative diseases in many low resource economies are likely to hamper the growth of this market.

The recent COVID-19 global pandemic has also impacted the point of care diagnostics market. Demand from the main end-users has increased as key regions and countries demanded for rapid testing kits in order to detect the COVID infection at the earliest. The rapidly growing number of COVID-19 cases and the growing pressure on governments to improve patient management has boosted the demand for rapid testing kits that can be effectively used in point-of-care settings.

“The glucose monitoring products segment to witness the highest growth rate in point of care diagnostics market, by product, during the forecast period.”
The glucose monitoring products segment is expected to witness the highest growth rate during the forecast period. The high growth in this owes to the high prevalence of diabetes, ongoing technological advancements in blood glucose self-monitoring devices, and growing patient awareness about the availability POC products to easily monitor blood glucose level at home.

“The lateral flow assays segment accounted for the largest share of the point of care diagnostics market, by platform, in 2020.”
The latetal flow assays segment accounted for the largest share of the point of care diagnotics market in 2020. The increasing adoption of lateral flow assays in POC testing as a replacement for lengthy, conventional laboratory procedures are playing a critical factor supporting the growth of this segment.

“The OTC testing segment accounted for the largest share of the point of care diagnostics, by mode of purchase, in 2020”
OTC testing products are used for glucose monitoring, pregnancy & fertility testing, infectious disease testing, and cholesterol-level testing. Moreover, many PoC devices available without prescription in many developing nations and increase in online purchase of OCT POC product are driving the demand for OTC POC testing products.

“The Hospitals & Critical Care Centers segment accounted for the largest share of the point of care diagnostics, by end users, in 2020”
Hospitals and clinics make use of POC devices for improving patient care and treatment efficiency. One of the main advantages of using POC devices in hospitals or clinical settings over laboratory tests is that they have a faster turnaround time for testing as compared to a laboratory. Increase in the awareness of the benefits associated with the POC diagnostics for the treatment/monitoring of various patients in hospitals/critical care centers are accelerating the use of POC devices among these end users.

“The Asia Pacific market to grow at the highest CAGR during the forecast period.”
The point of care diagnostics market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Government efforts to increase awareness related rapid diagnostic devices at point of care , rising healthcare expenditure, increasing healthcare expenditures, increasing number of hospitals and clinical diagnostic laboratories in India and China, and growing collaborations among players in the region are also expected to drive pount of care diagnostics market growth in Aisa Pacific.

Breakdown of supply-side primary interviews:
• By Company Type: Tier 1: 25%, Tier 2: 30%, and Tier 3: 45%
• By Designation: C-level: 26%, D-level: 30%, and Others: 44%
• By Region: North America: 39%, Europe: 24%, APAC: 21%, Latin America: 10%, and the Middle East & Africa: 5%

The major players operating in the point of care diagnosticsmarket are Roche Diagnostics (Switzerland), Siemens Healthineers (Germany), Danaher Corporation (US), Becton Dickinson and Company (US), Abbott Laboratories (US), Quidel Diagnostics (US), and Chembio Diagnostics (US). Other prominent players operating in this market are EKF Diagnostics (UK), Trinity Biotech (Ireland), and Fluxergy (France).

Research Coverage
This report studies the point of care diagnosticsmarket based on the product, mode of purchase, platform end-user, and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five major regions (and the respective countries in these regions).

Key Benefits of Buying the Report
This report focuses on various levels of analysis—industry trends, market share of top players, and company profiles, which together form basic views and analyze the competitive landscape, emerging segments of the point of care diagnosticsmarket, and high-growth regions and their drivers, restraints, opportunities, and challenges. The report will help both established firms as well as new entrants/smaller firms to gauge the pulse of the market and garner greater market shares.

【レポートの目次】

1 INTRODUCTION 32
1.1 OBJECTIVES OF THE STUDY 32
1.2 MARKET DEFINITION 32
1.3 MARKET SCOPE 33
1.3.1 MARKETS COVERED 33
1.3.2 YEARS CONSIDERED FOR THE STUDY 34
1.4 CURRENCY USED FOR THE STUDY 34
1.5 MAJOR MARKET STAKEHOLDERS 34
1.6 SUMMARY OF CHANGES 35
2 RESEARCH METHODOLOGY 36
2.1 RESEARCH DATA 36
FIGURE 1 RESEARCH DESIGN 36
2.1.1 SECONDARY DATA 37
2.1.1.1 Secondary sources 38
2.1.2 PRIMARY DATA 38
FIGURE 2 BREAKDOWN OF PRIMARIES: POINT-OF-CARE DIAGNOSTICS MARKET 39
2.2 MARKET ESTIMATION METHODOLOGY 39
FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 40
2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION 40
2.2.2 END USER-BASED MARKET ESTIMATION 41
FIGURE 4 MARKET SIZE ESTIMATION: POINT-OF-CARE DIAGNOSTICS MARKET 41
2.2.3 PRIMARY RESEARCH VALIDATION 41
2.3 DATA TRIANGULATION 42
FIGURE 5 DATA TRIANGULATION METHODOLOGY 42
2.4 RESEARCH ASSUMPTIONS 43
2.5 RESEARCH LIMITATIONS 43
3 EXECUTIVE SUMMARY 44
FIGURE 6 POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2020 VS. 2025 (USD MILLION) 44
FIGURE 7 POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM,
2020 VS. 2025 (USD MILLION) 45
FIGURE 8 POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE,
2020 VS. 2025 (USD MILLION) 46
FIGURE 9 POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER,
2020 VS. 2025 (USD MILLION) 46
FIGURE 10 GEOGRAPHICAL SNAPSHOT OF THE POINT-OF-CARE DIAGNOSTICS MARKET 47

4 PREMIUM INSIGHTS 48
4.1 POINT-OF-CARE DIAGNOSTICS MARKET OVERVIEW 48
FIGURE 11 INCREASINGLY SUPPORTIVE GOVERNMENT POLICIES AND RISING PREVALENCE OF TARGET DISEASES ARE DRIVING THE MARKET GROWTH 48
4.2 POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2020 49
FIGURE 12 OTC TESTING PRODUCTS DOMINATE THE POINT-OF-CARE DIAGNOSTICS MARKET IN 2020 49
4.3 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET 50
FIGURE 13 HOME CARE SETTINGS WERE THE LARGEST END-USER SEGMENT IN THE APAC POC DIAGNOSTICS MARKET IN 2020 50
4.4 POINT-OF-CARE DIAGNOSTICS MARKET, BY REGION 51
FIGURE 14 APAC TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD (2020–2025) 51
5 MARKET OVERVIEW 52
5.1 INTRODUCTION 52
5.2 MARKET DYNAMICS 52
FIGURE 15 POINT-OF-CARE DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 52
5.2.1 DRIVERS 53
5.2.1.1 High prevalence of infectious diseases 53
5.2.1.2 Increasing incidence of target conditions 53
5.2.1.3 Supportive government policies 54
5.2.1.4 Dearth of skilled laboratory technicians 54
5.2.1.5 Rising number of CLIA-waived POC tests 55
TABLE 1 RECENT WAIVERS FOR MARKET PRODUCTS 55
5.2.2 RESTRAINTS 55
5.2.2.1 Pricing pressure owing to reimbursement cuts and budget constraints 55
5.2.2.2 Stringent regulatory policies 56
5.2.3 OPPORTUNITIES 56
5.2.3.1 Emerging markets 56
5.2.3.2 Healthcare decentralization 57
5.2.3.3 Increasing provider awareness about novel technologies 57
5.2.3.4 POC tests with multiplexing capabilities 58
5.2.3.5 Growing investments and funding for product development 58
5.2.4 CHALLENGES 59
5.2.4.1 Lack of alignment with definitive central lab methods 59
5.2.4.2 Inadequate adoption of POC devices in professional settings 59
5.2.4.3 Reluctance to change existing diagnostic practices 60
5.2.4.4 Premium pricing of novel platforms 60

5.3 TECHNOLOGY ANALYSIS: EMERGING POINT-OF-CARE APPLICATIONS 60
5.3.1 SEPSIS BIOMARKERS 60
5.3.2 STROKE/CARDIAC MARKERS 61
5.3.3 THYROID TESTING 62
5.3.4 DNA TESTING 62
5.3.5 ENDOCRINE TESTING 62
5.3.6 RESPIRATORY DIAGNOSTICS 62
5.4 GLOBAL REGULATORY LANDSCAPE 63
5.5 INDUSTRY TRENDS RELATED TO COVID-19 64
5.6 VALUE CHAIN ANALYSIS 64
FIGURE 16 VALUE CHAIN ANALYSIS—MAXIMUM VALUE ADDED DURING
THE REGULATION AND DISTRIBUTION STAGES 64
5.7 PRICING TREND ANALYSIS 65
TABLE 2 AVERAGE PRICE OF GLUCOSE MONITORING AND CARDIOMETABOLIC MONITORING PRODUCTS, BY COUNTRY, 2019 (USD) 65
TABLE 3 AVERAGE PRICE OF INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2019 (USD) 66
TABLE 4 AVERAGE PRICE OF OTHER POINT-OF-CARE TESTING PRODUCTS,
BY COUNTRY, 2019 (USD) 66
5.8 ECOSYSTEM COVERAGE: PARENT MARKET (IN VITRO DIAGNOSTICS) 67
5.9 USE CASES: POINT-OF-CARE DIAGNOSTICS MARKET 68
5.9.1 REVENUE OPPORTUNITIES: IVD ASSAY DEVELOPMENT SERVICES 68
5.9.2 REVENUE OPPORTUNITIES: IVD CONTRACT RESEARCH SERVICES 69
6 POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT 70
6.1 INTRODUCTION 71
TABLE 5 POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 71
6.2 GLUCOSE MONITORING PRODUCTS 71
TABLE 6 POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2018–2025 (USD MILLION) 72
TABLE 7 POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY PLATFORM, 2018–2025 (USD MILLION) 72
TABLE 8 POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY MODE OF PURCHASE, 2018–2025 (USD MILLION) 73
TABLE 9 POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY END USER, 2018–2025 (USD MILLION) 73
TABLE 10 POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY REGION, 2018–2025 (USD MILLION) 73
6.2.1 STRIPS 74
6.2.1.1 Strips make blood glucose testing easy and hassle-free 74
TABLE 11 GLUCOSE MONITORING STRIPS MARKET, BY REGION,
2018–2025 (USD MILLION) 74
6.2.2 METERS 74
6.2.2.1 Blood glucose meters are extremely helpful in the monitoring of blood glucose levels and adjusting therapeutic regimens 74
TABLE 12 GLUCOSE MONITORING METERS MARKET, BY REGION,
2018–2025 (USD MILLION) 75
6.2.3 LANCETS & LANCING DEVICES 75
6.2.3.1 Lancets & lancing devices segment to grow at the lowest CAGR in the glucose monitoring products market 75
TABLE 13 GLUCOSE MONITORING LANCETS & LANCING DEVICES MARKET, BY REGION, 2018–2025 (USD MILLION) 75
6.3 CARDIOMETABOLIC MONITORING PRODUCTS 76
TABLE 14 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2018–2025 (USD MILLION) 76
TABLE 15 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY PLATFORM, 2018–2025 (USD MILLION) 76
TABLE 16 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY MODE OF PURCHASE,
2018–2025 (USD MILLION) 76
TABLE 17 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY END USER, 2018–2025 (USD MILLION) 77
TABLE 18 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY REGION, 2018–2025 (USD MILLION) 77
6.3.1 CARDIAC MARKER TESTING PRODUCTS 77
6.3.1.1 Rising government initiatives for CVD research will contribute to market growth 77
TABLE 19 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY MODE OF PURCHASE, 2018–2025 (USD MILLION) 78
TABLE 20 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY END USER, 2018–2025 (USD MILLION) 78
TABLE 21 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY REGION, 2018–2025 (USD MILLION) 78
6.3.2 BLOOD GAS/ELECTROLYTE TESTING PRODUCTS 79
6.3.2.1 Technological advancements in blood gas/electrolyte products will drive the growth of this market segment 79
TABLE 22 POINT-OF-CARE DIAGNOSTICS MARKET FOR BLOOD GAS/ELECTROLYTE TESTING PRODUCTS, BY MODE OF PURCHASE, 2018–2025 (USD MILLION) 79
TABLE 23 POINT-OF-CARE DIAGNOSTICS MARKET FOR BLOOD GAS/ELECTROLYTE TESTING PRODUCTS, BY END USER, 2018–2025 (USD MILLION) 79
TABLE 24 POINT-OF-CARE DIAGNOSTICS MARKET FOR BLOOD GAS/ELECTROLYTE TESTING PRODUCTS, BY REGION, 2018–2025 (USD MILLION) 80
6.3.3 HBA1C TESTING PRODUCTS 80
6.3.3.1 Government initiatives are promoting the regular use of HbA1c testing 80
TABLE 25 POINT-OF-CARE DIAGNOSTICS MARKET FOR HBA1C TESTING PRODUCTS,
BY MODE OF PURCHASE, 2018–2025 (USD MILLION) 81
TABLE 26 POINT-OF-CARE DIAGNOSTICS MARKET FOR HBA1C TESTING PRODUCTS,
BY END USER, 2018–2025 (USD MILLION) 81
TABLE 27 POINT-OF-CARE DIAGNOSTICS MARKET FOR HBA1C TESTING PRODUCTS,
BY REGION, 2018–2025 (USD MILLION) 81

6.4 INFECTIOUS DISEASE TESTING PRODUCTS 82
TABLE 28 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2018–2025 (USD MILLION) 82
TABLE 29 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY PLATFORM, 2018–2025 (USD MILLION) 82
TABLE 30 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY MODE OF PURCHASE, 2018–2025 (USD MILLION) 83
TABLE 31 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY END USER, 2018–2025 (USD MILLION) 83
TABLE 32 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2018–2025 (USD MILLION) 83
6.4.1 HIV TESTING PRODUCTS 84
6.4.1.1 Rising prevalence of HIV to drive market growth 84
TABLE 33 POINT-OF-CARE DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS,
BY MODE OF PURCHASE, 2018–2025 (USD MILLION) 84
TABLE 34 POINT-OF-CARE DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS,
BY END USER, 2018–2025 (USD MILLION) 84
TABLE 35 POINT-OF-CARE DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS,
BY REGION, 2018–2025 (USD MILLION) 85
6.4.2 RESPIRATORY INFECTION TESTING PRODUCTS 85
6.4.2.1 POCT products for the diagnosis of respiratory infections offer lower sensitivity as compared to other tests 85
TABLE 36 POINT-OF-CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY MODE OF PURCHASE, 2018–2025 (USD MILLION) 86
TABLE 37 POINT-OF-CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY END USER, 2018–2025 (USD MILLION) 86
TABLE 38 POINT-OF-CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY REGION, 2018–2025 (USD MILLION) 86
6.4.3 HEPATITIS C TESTING PRODUCTS 87
6.4.3.1 Central and East Asia are among the highly affected regions with Hepatitis C 87
TABLE 39 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS, BY MODE OF PURCHASE, 2018–2025 (USD MILLION) 87
TABLE 40 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS, BY END USER, 2018–2025 (USD MILLION) 88
TABLE 41 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS, BY REGION, 2018–2025 (USD MILLION) 88
6.4.4 HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS 88
6.4.4.1 Rising prevalence of HAIs is the key factor driving market growth 88
TABLE 42 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY MODE OF PURCHASE,
2018–2025 (USD MILLION) 89
TABLE 43 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY END USER, 2018–2025 (USD MILLION) 89
TABLE 44 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY REGION, 2018–2025 (USD MILLION) 89
6.4.5 INFLUENZA TESTING PRODUCTS 90
6.4.5.1 Rising influenza prevalence has driven the demand for influenza testing products 90
TABLE 45 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY MODE OF PURCHASE, 2018–2025 (USD MILLION) 90
TABLE 46 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY END USER, 2018–2025 (USD MILLION) 90
TABLE 47 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY REGION, 2018–2025 (USD MILLION) 91
6.4.6 TROPICAL DISEASE TESTING PRODUCTS 91
6.4.6.1 Increasing government funding for the use of POC in tropical disease testing will support market growth 91
TABLE 48 POINT-OF-CARE DIAGNOSTICS MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY MODE OF PURCHASE, 2018–2025 (USD MILLION) 92
TABLE 49 POINT-OF-CARE DIAGNOSTICS MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY END USER, 2018–2025 (USD MILLION) 92
TABLE 50 POINT-OF-CARE DIAGNOSTICS MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY REGION, 2018–2025 (USD MILLION) 92
6.4.7 SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS 93
6.4.7.1 Privacy and confidentiality issues are the key factors leading to the adoption of POC STD testing products 93
TABLE 51 POINT-OF-CARE DIAGNOSTICS MARKET FOR STD TESTING PRODUCTS,
BY MODE OF PURCHASE, 2018–2025 (USD MILLION) 93
TABLE 52 POINT-OF-CARE DIAGNOSTICS MARKET FOR STD TESTING PRODUCTS,
BY END USER, 2018–2025 (USD MILLION) 94
TABLE 53 POINT-OF-CARE DIAGNOSTICS MARKET FOR STD TESTING PRODUCTS,
BY REGION, 2018–2025 (USD MILLION) 94
6.4.8 OTHER INFECTIOUS DISEASE TESTING PRODUCTS 94
TABLE 54 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY MODE OF PURCHASE, 2018–2025 (USD MILLION) 95
TABLE 55 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY END USER, 2018–2025 (USD MILLION) 95
TABLE 56 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2018–2025 (USD MILLION) 95
6.5 COAGULATION MONITORING PRODUCTS 96
TABLE 57 POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2018–2025 (USD MILLION) 96
TABLE 58 POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY PLATFORM, 2018–2025 (USD MILLION) 97
TABLE 59 POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY MODE OF PURCHASE, 2018–2025 (USD MILLION) 97
TABLE 60 POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY END USER, 2018–2025 (USD MILLION) 97
TABLE 61 POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY REGION, 2018–2025 (USD MILLION) 98
6.5.1 PT/INR TESTING PRODUCTS 98
6.5.1.1 PT/INR is one of the most commonly used coagulation monitoring methods 98
TABLE 62 POINT-OF-CARE DIAGNOSTICS MARKET FOR PT/INR TESTING PRODUCTS,
BY MODE OF PURCHASE, 2018–2025 (USD MILLION) 98
TABLE 63 POINT-OF-CARE DIAGNOSTICS MARKET FOR PT/INR TESTING PRODUCTS,
BY END USER, 2018–2025 (USD MILLION) 99
TABLE 64 POINT-OF-CARE DIAGNOSTICS MARKET FOR PT/INR TESTING PRODUCTS,
BY REGION, 2018–2025 (USD MILLION) 99
6.5.2 ACT/APTT TESTING PRODUCTS 99
6.5.2.1 Rising number of patients undergoing angioplasty and dialysis globally to support market growth 99
TABLE 65 POINT-OF-CARE DIAGNOSTICS MARKET FOR ACT/APTT TESTING PRODUCTS, BY MODE OF PURCHASE, 2018–2025 (USD MILLION) 100
TABLE 66 POINT-OF-CARE DIAGNOSTICS MARKET FOR ACT/APTT TESTING PRODUCTS, BY END USER, 2018–2025 (USD MILLION) 100
TABLE 67 POINT-OF-CARE DIAGNOSTICS MARKET FOR ACT/APTT TESTING PRODUCTS, BY REGION, 2018–2025 (USD MILLION) 100
6.6 PREGNANCY & FERTILITY TESTING PRODUCTS 101
TABLE 68 POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2018–2025 (USD MILLION) 101
TABLE 69 POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY PLATFORM, 2018–2025 (USD MILLION) 101
TABLE 70 POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY MODE OF PURCHASE, 2018–2025 (USD MILLION) 102
TABLE 71 POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY END USER, 2018–2025 (USD MILLION) 102
TABLE 72 POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY REGION, 2018–2025 (USD MILLION) 102
6.6.1 PREGNANCY TESTING PRODUCTS 103
6.6.1.1 Rising inclination toward home testing to support market growth 103
TABLE 73 POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY TESTING PRODUCTS, BY MODE OF PURCHASE, 2018–2025 (USD MILLION) 103
TABLE 74 POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY TESTING PRODUCTS, BY END USER, 2018–2025 (USD MILLION) 103
TABLE 75 POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY TESTING PRODUCTS, BY REGION, 2018–2025 (USD MILLION) 104
6.6.2 FERTILITY TESTING PRODUCTS 104
6.6.2.1 Increasing awareness of fertility testing to drive market growth 104
TABLE 76 POINT-OF-CARE DIAGNOSTICS MARKET FOR FERTILITY TESTING PRODUCTS, BY MODE OF PURCHASE, 2018–2025 (USD MILLION) 105
TABLE 77 POINT-OF-CARE DIAGNOSTICS MARKET FOR FERTILITY TESTING PRODUCTS, BY END USER, 2018–2025 (USD MILLION) 105
TABLE 78 POINT-OF-CARE DIAGNOSTICS MARKET FOR FERTILITY TESTING PRODUCTS, BY REGION, 2018–2025 (USD MILLION) 105
6.7 TUMOR/CANCER MARKER TESTING PRODUCTS 106
6.7.1 INCREASING INVESTMENTS FOR RESEARCH RELATED TO POC CANCER TESTING ARE DRIVING MARKET GROWTH 106
TABLE 79 POINT-OF-CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY PLATFORM, 2018–2025 (USD MILLION) 106
TABLE 80 POINT-OF-CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY MODE OF PURCHASE, 2018–2025 (USD MILLION) 106
TABLE 81 POINT-OF-CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY END USER, 2018–2025 (USD MILLION) 107
TABLE 82 POINT-OF-CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY REGION, 2018–2025 (USD MILLION) 107
6.8 URINALYSIS TESTING PRODUCTS 107
6.8.1 RISING PREVALENCE OF URINARY TRACT INFECTIONS IS DRIVING MARKET GROWTH 107
TABLE 83 POINT-OF-CARE DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS, BY PLATFORM, 2018–2025 (USD MILLION) 108
TABLE 84 POINT-OF-CARE DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS, BY MODE OF PURCHASE, 2018–2025 (USD MILLION) 108
TABLE 85 POINT-OF-CARE DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS, BY END USER, 2018–2025 (USD MILLION) 108
TABLE 86 POINT-OF-CARE DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS, BY REGION, 2018–2025 (USD MILLION) 109
6.9 CHOLESTEROL TESTING PRODUCTS 109
6.9.1 RISING OBESITY LEVELS & CARDIOVASCULAR DISORDER INCIDENCE ARE THE KEY FACTORS SUPPORTING MARKET GROWTH 109
TABLE 87 POINT-OF-CARE DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY PLATFORM, 2018–2025 (USD MILLION) 109
TABLE 88 POINT-OF-CARE DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY MODE OF PURCHASE, 2018–2025 (USD MILLION) 110
TABLE 89 POINT-OF-CARE DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY END USER, 2018–2025 (USD MILLION) 110
TABLE 90 POINT-OF-CARE DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY REGION, 2018–2025 (USD MILLION) 110
6.10 HEMATOLOGY TESTING PRODUCTS 111
6.10.1 PREFERENCE FOR LABORATORY-BASED TESTS AMONG USERS WILL IMPEDE MARKET GROWTH 111
TABLE 91 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY PLATFORM, 2018–2025 (USD MILLION) 111
TABLE 92 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY MODE OF PURCHASE, 2018–2025 (USD MILLION) 111
TABLE 93 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY END USER, 2018–2025 (USD MILLION) 112
TABLE 94 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY REGION, 2018–2025 (USD MILLION) 112
6.11 DRUGS-OF-ABUSE TESTING PRODUCTS 112
6.11.1 RISING CONSUMPTION OF ILLICIT DRUGS HAS BOOSTED DEMAND FOR TESTING 112
TABLE 95 POINT-OF-CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY PLATFORM, 2018–2025 (USD MILLION) 113
TABLE 96 POINT-OF-CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY MODE OF PURCHASE, 2018–2025 (USD MILLION) 113
TABLE 97 POINT-OF-CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY END USER, 2018–2025 (USD MILLION) 113
TABLE 98 POINT-OF-CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY REGION, 2018–2025 (USD MILLION) 114
6.12 FECAL OCCULT TESTING PRODUCTS 114
6.12.1 LACK OF PROPER TRAINING IN THE USE OF FECAL OCCULT TESTING
TO HAMPER MARKET ADOPTION 114
TABLE 99 POINT-OF-CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY PLATFORM, 2018–2025 (USD MILLION) 114
TABLE 100 POINT-OF-CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY MODE OF PURCHASE, 2018–2025 (USD MILLION) 115
TABLE 101 POINT-OF-CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY END USER, 2018–2025 (USD MILLION) 115
TABLE 102 POINT-OF-CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY REGION, 2018–2025 (USD MILLION) 115
6.13 OTHER POC PRODUCTS 116
TABLE 103 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER POC PRODUCTS,
BY PLATFORM, 2018–2025 (USD MILLION) 116
TABLE 104 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER PRODUCTS,
BY MODE OF PURCHASE, 2018–2025 (USD MILLION) 116
TABLE 105 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER POC PRODUCTS,
BY END USER, 2018–2025 (USD MILLION) 117
TABLE 106 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER POC PRODUCTS,
BY REGION, 2018–2025 (USD MILLION) 117

7 POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM 118
7.1 INTRODUCTION 119
TABLE 107 POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM,
2018–2025 (USD MILLION) 119
7.2 LATERAL FLOW ASSAYS 119
7.2.1 TECHNOLOGICAL ADVANCEMENTS AND INCREASING ADOPTION OF LFA ARE SUPPORTING MARKET GROWTH 119
TABLE 108 POINT-OF-CARE DIAGNOSTICS MARKET FOR LATERAL FLOW ASSAYS,
BY REGION, 2018–2025 (USD MILLION) 120
7.3 IMMUNOASSAYS 120
7.3.1 RISING INCIDENCE OF CANCER AND GROWING AWARENESS ABOUT IMMUNOASSAY PLATFORMS TO SUPPORT MARKET GROWTH 120
TABLE 109 POINT-OF-CARE DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY REGION, 2018–2025 (USD MILLION) 121
7.4 MICROFLUIDICS 121
7.4.1 MICROFLUIDICS IS AN EMERGING PLATFORM IN
THE POC DIAGNOSTICS MARKET 121
TABLE 110 POINT-OF-CARE DIAGNOSTICS MARKET FOR MICROFLUIDICS, BY REGION, 2018–2025 (USD MILLION) 122
7.5 DIPSTICKS 122
7.5.1 DIPSTICKS HELP IN THE ROUTINE ANALYSIS OF SEVERAL MEDICAL CONDITIONS 122
TABLE 111 POINT-OF-CARE DIAGNOSTICS MARKET FOR DIPSTICKS, BY REGION,
2018–2025 (USD MILLION) 123
7.6 MOLECULAR DIAGNOSTICS 123
7.6.1 INCREASING INITIATIVES BY MARKET PLAYERS FOR DEVELOPING POC MOLECULAR DIAGNOSTIC PRODUCTS TO DRIVE MARKET GROWTH 123
TABLE 112 POINT-OF-CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY REGION, 2018–2025 (USD MILLION) 124
8 POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE 125
8.1 INTRODUCTION 126
TABLE 113 POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE,
2018–2025 (USD MILLION) 126
8.2 OTC TESTING PRODUCTS 126
8.2.1 RISING FOCUS ON HOME CARE IS EXPECTED TO BOOST THE DEMAND FOR OTC TESTING IN THE COMING YEARS 126
TABLE 114 OTC POINT-OF-CARE TESTING PRODUCTS MARKET, BY REGION,
2018–2025 (USD MILLION) 127
8.3 PRESCRIPTION-BASED TESTING PRODUCTS 127
8.3.1 GROWING PREVALENCE OF LIFESTYLE DISEASES AND FAVORABLE REIMBURSEMENT HAVE DRIVEN MARKET GROWTH 127
TABLE 115 PRESCRIPTION-BASED POINT-OF-CARE TESTING PRODUCTS MARKET,
BY REGION, 2018–2025 (USD MILLION) 128
9 POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER 129
9.1 INTRODUCTION 130
TABLE 116 POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER,
2018–2025 (USD MILLION) 130
9.2 OUTPATIENT & AMBULATORY CARE FACILITIES 130
9.2.1 RAPID RESULT GENERATION AND AVAILABILITY OF IMMEDIATE PATIENT CARE ARE THE MAJOR FACTORS DRIVING MARKET GROWTH 130
TABLE 117 POINT-OF-CARE DIAGNOSTICS MARKET FOR OUTPATIENT & AMBULATORY CARE FACILITIES, BY REGION, 2018–2025 (USD MILLION) 131
9.3 HOSPITALS & CRITICAL CARE CENTERS 131
9.3.1 HOSPITALS ARE AMONG THE LARGEST END USERS OF POC DIAGNOSTICS 131
TABLE 118 POINT-OF-CARE DIAGNOSTICS MARKET FOR HOSPITALS & CRITICAL CARE CENTERS, BY REGION, 2018–2025 (USD MILLION) 132
9.4 HOME CARE SETTINGS 132
9.4.1 INCREASING INCLINATION TOWARD HOME HEALTHCARE IS DRIVING THE GROWTH OF THIS END-USER SEGMENT 132
TABLE 119 POINT-OF-CARE DIAGNOSTICS MARKET FOR HOME CARE SETTINGS,
BY REGION, 2018–2025 (USD MILLION) 133
9.5 OTHER END USERS 133
TABLE 120 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2018–2025 (USD MILLION) 133
10 POINT-OF-CARE DIAGNOSTICS MARKET, BY REGION 134
10.1 INTRODUCTION 135
TABLE 121 POINT-OF-CARE DIAGNOSTICS MARKET, BY REGION,
2018–2025 (USD MILLION) 135
10.2 NORTH AMERICA 136
FIGURE 17 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET SNAPSHOT 136
TABLE 122 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 137
TABLE 123 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2018–2025 (USD MILLION) 137
TABLE 124 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2018–2025 (USD MILLION) 138
TABLE 125 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE,
2018–2025 (USD MILLION) 138
TABLE 126 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2018–2025 (USD MILLION) 138
TABLE 127 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE,
2018–2025 (USD MILLION) 139
TABLE 128 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2018–2025 (USD MILLION) 139
TABLE 129 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2018–2025 (USD MILLION) 139
TABLE 130 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2018–2025 (USD MILLION) 140
TABLE 131 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2018–2025 (USD MILLION) 140
10.2.1 US 140
10.2.1.1 The US dominates the North American market for POC diagnostics 140
TABLE 132 US: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 142
10.2.2 CANADA 142
10.2.2.1 Rising government initiatives to support the growth of the POC diagnostics market in Canada 142
TABLE 133 CANADA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 143
10.3 EUROPE 144
TABLE 134 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 144
TABLE 135 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 144
TABLE 136 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2018–2025 (USD MILLION) 145
TABLE 137 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2018–2025 (USD MILLION) 145
TABLE 138 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2018–2025 (USD MILLION) 145
TABLE 139 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2018–2025 (USD MILLION) 146
TABLE 140 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2018–2025 (USD MILLION) 146
TABLE 141 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM,
2018–2025 (USD MILLION) 146
TABLE 142 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2018–2025 (USD MILLION) 147
TABLE 143 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER,
2018–2025 (USD MILLION) 147
10.3.1 GERMANY 147
10.3.1.1 Germany accounts for the largest share of the European market 147
TABLE 144 GERMANY: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 148
10.3.2 FRANCE 148
10.3.2.1 Growing public-private collaborations for product development to drive market growth 148
TABLE 145 FRANCE: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 149
10.3.3 UK 150
10.3.3.1 Growing awareness of the benefits offered by POC diagnostics to support market growth in the UK 150
TABLE 146 UK: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 151
10.3.4 ITALY 151
10.3.4.1 Rising prevalence of chronic diseases in Italy to drive the demand for point-of-care diagnostics 151
TABLE 147 ITALY: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 152
10.3.5 SPAIN 152
10.3.5.1 Increasing funding for research in Spain to boost market growth 152
TABLE 148 SPAIN: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 153
10.3.6 REST OF EUROPE 153
TABLE 149 ROE: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 154
10.4 ASIA PACIFIC 154
FIGURE 18 APAC: POINT-OF-CARE DIAGNOSTICS MARKET SNAPSHOT 155
TABLE 150 APAC: POINT-OF-CARE DIAGNOSTICS MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 155
TABLE 151 APAC: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 156
TABLE 152 APAC: POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2018–2025 (USD MILLION) 156
TABLE 153 APAC: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2018–2025 (USD MILLION) 157
TABLE 154 APAC: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2018–2025 (USD MILLION) 157
TABLE 155 APAC: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2018–2025 (USD MILLION) 157
TABLE 156 APAC: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2018–2025 (USD MILLION) 158
TABLE 157 APAC: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM,
2018–2025 (USD MILLION) 158
TABLE 158 APAC: POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2018–2025 (USD MILLION) 158
TABLE 159 APAC: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER,
2018–2025 (USD MILLION) 159
10.4.1 JAPAN 159
10.4.1.1 Japan to dominate the APAC POC diagnostics market during the forecast period 159
TABLE 160 JAPAN: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 160
10.4.2 CHINA 160
10.4.2.1 Rising investments by market players and the Chinese government to drive market growth 160
TABLE 161 CHINA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 161
10.4.3 INDIA 162
10.4.3.1 High burden of chronic diseases to support market growth 162
TABLE 162 INDIA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 163
10.4.4 AUSTRALIA 163
10.4.4.1 High burden of chronic diseases to support market growth 163
TABLE 163 AUSTRALIA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 164
10.4.5 SOUTH KOREA 164
10.4.5.1 Increased funding and product development to propel market growth 164
TABLE 164 SOUTH KOREA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2018–2025 (USD MILLION) 165
10.4.6 REST OF ASIA PACIFIC 165
TABLE 165 ROAPAC: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 166
10.5 LATIN AMERICA 166
TABLE 166 LATAM: POINT-OF-CARE DIAGNOSTICS MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 167
TABLE 167 LATAM: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 167
TABLE 168 LATAM: POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2018–2025 (USD MILLION) 168
TABLE 169 LATAM: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2018–2025 (USD MILLION) 168
TABLE 170 LATAM: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2018–2025 (USD MILLION) 168
TABLE 171 LATAM: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2018–2025 (USD MILLION) 169
TABLE 172 LATAM: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2018–2025 (USD MILLION) 169
TABLE 173 LATAM: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM,
2018–2025 (USD MILLION) 169
TABLE 174 LATAM: POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2018–2025 (USD MILLION) 170
TABLE 175 LATAM: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER,
2018–2025 (USD MILLION) 170
10.5.1 BRAZIL 170
10.5.1.1 Rising prevalence of diabetes to support market growth in Brazil 170
TABLE 176 BRAZIL: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 171
10.5.2 MEXICO 171
10.5.2.1 Rising prevalence of diabetes and cancer to support market growth in Mexico 171
TABLE 177 MEXICO: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 172
10.5.3 REST OF LATIN AMERICA 173
TABLE 178 ROLATAM: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 173
10.6 MIDDLE EAST & AFRICA 173
10.6.1 RISING PREVALENCE OF CANCER TO SUPPORT MARKET GROWTH IN THE MEA 173
TABLE 179 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET,
BY PRODUCT, 2018–2025 (USD MILLION) 174
TABLE 180 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2018–2025 (USD MILLION) 175
TABLE 181 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE,
2018–2025 (USD MILLION) 175
TABLE 182 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE,
2018–2025 (USD MILLION) 175
TABLE 183 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE,
2018–2025 (USD MILLION) 176
TABLE 184 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE,
2018–2025 (USD MILLION) 176
TABLE 185 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET,
BY PLATFORM, 2018–2025 (USD MILLION) 176
TABLE 186 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET,
BY MODE OF PURCHASE, 2018–2025 (USD MILLION) 177
TABLE 187 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET,
BY END USER, 2018–2025 (USD MILLION) 177
11 COMPETITIVE LANDSCAPE 178
11.1 OVERVIEW 178
FIGURE 19 KEY DEVELOPMENTS IN THE POINT-OF-
CARE DIAGNOSTICS MARKET (2017–2020) 179
11.2 MARKET SHARE ANALYSIS (2019) 180
FIGURE 20 ROCHE DIAGNOSTICS HELD THE LEADING POSITION IN THE MARKET IN 2019 180
11.3 COMPETITIVE SCENARIO (2016–2020) 181
FIGURE 21 STRATEGIC OVERVIEW: MAJOR PLAYERS (2016–2020) 181
11.3.1 KEY PRODUCT LAUNCHES & PRODUCT APPROVALS (2016–2020) 181
11.3.2 KEY ACQUISITIONS (2016–2020) 182
11.3.3 KEY AGREEMENTS, CONTRACTS, AND PARTNERSHIPS (2016–2020) 182
11.4 COMPETITIVE LEADERSHIP MAPPING: MAJOR GLOBAL PLAYERS (AS OF 2019) 183
11.4.1 STARS 183
11.4.2 EMERGING LEADERS 183
11.4.3 PERVASIVE PLAYERS 183
11.4.4 PARTICIPANTS 183
FIGURE 22 POINT-OF-CARE DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING, 2019 (MAJOR GLOBAL PLAYERS) 184
11.5 COMPETITIVE LEADERSHIP MAPPING: EMERGING COMPANIES/SMES/START-UPS
(AS OF 2019) 185
11.5.1 PROGRESSIVE COMPANIES 185
11.5.2 STARTING BLOCKS 185
11.5.3 RESPONSIVE COMPANIES 185
11.5.4 DYNAMIC COMPANIES 185
12 COMPANY PROFILES 187
(Business Overview, Products Offered, Recent Developments, MnM View)*
12.1 ROCHE DIAGNOSTICS 187
FIGURE 24 ROCHE DIAGNOSTICS: COMPANY SNAPSHOT 187
12.2 SIEMENS HEALTHINEERS 191
FIGURE 25 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT 191
12.3 DANAHER CORPORATION 195
FIGURE 26 DANAHER CORPORATION: COMPANY SNAPSHOT 195
12.4 BECTON, DICKINSON AND COMPANY 198
FIGURE 27 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT 198
12.5 ABBOTT LABORATORIES 201
FIGURE 28 ABBOTT LABORATORIES: COMPANY SNAPSHOT 201
12.6 QUIDEL CORPORATION 205
FIGURE 29 QUIDEL CORPORATION: COMPANY SNAPSHOT 205
12.7 CHEMBIO DIAGNOSTICS 208
FIGURE 30 CHEMBIO DIAGNOSTICS: COMPANY SNAPSHOT 208
12.8 JOHNSON & JOHNSON 212
FIGURE 31 JOHNSON & JOHNSON: COMPANY SNAPSHOT 212
12.9 EKF DIAGNOSTICS 214
FIGURE 32 EKF DIAGNOSTICS: COMPANY SNAPSHOT 214
12.10 TRINITY BIOTECH 217
FIGURE 33 TRINITY BIOTECH: COMPANY SNAPSHOT 217
12.11 ACCUBIOTECH 219
12.12 INSTRUMENTATION LABORATORY (A WERFEN COMPANY) 222
12.13 NOVA BIOMEDICAL 224
12.14 PTS DIAGNOSTICS 226
12.15 SEKISUI DIAGNOSTICS 228
12.16 FLUXERGY 230
*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.
13 APPENDIX 232
13.1 DISCUSSION GUIDE 232
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 237
13.3 AVAILABLE CUSTOMIZATIONS 239
13.4 RELATED REPORTS 239
13.5 AUTHOR DETAILS 240

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[世界のポイントオブケア/迅速診断市場(~2025年):製品別(ブドウ糖、感染症(C型肝炎、インフルエンザ)、凝固)、プラットフォーム別(マイクロフルイディクス、イムノアッセイ)、購入方法別(処方箋、OTC)、エンドユーザー別(病院、Eコマース、在宅医療)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆